Amanta Healthcare Ipo is bringing an IPO to expand its business, which will expand its business by taking money from the public for the first time, for which 126 crores are being raised from the public, whose IPO is opening on 1 September 2025, which the public will be able to apply for through any broker and anyone who invests in the IPO can get an opportunity to earn from it.
Amanta Healthcare IPO will open for subscription on September 1, 2025, and will close on September 3, 2025. The allotment of Amanta Healthcare IPO is expected to be finalized on September 4, 2025. Amanta Healthcare IPO will be listed on BSE and NSE, whose a tentative listing date fixed.
Amanta Healthcare IPO is a book build issue of ₹126.00 crore. The issue is entirely a fresh issue of 1.00 crore shares aggregating to ₹126.00 crore.
The investment required for a retail investor is ₹14,994 (119 shares) (based on the upper price). The lot size investment for SNII is 14 lots (1,666 shares), amounting to ₹2,09,916, and for BNII it is 67 lots (7,973 shares), amounting to ₹10,04,598.
About the Company
The company is a pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of sterile liquid products, including parenteral products, packed in plastic containers using Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technology. The company manufactures large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) in 6 therapeutic segments. Additionally, the company also manufactures medical devices. It offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types, and container fill-volume ranging from 2ml to 1000 ml.
Amanta Healthcare Ltd, a pharmaceutical company engaged in sterile liquid and parenteral products, is coming up with its Initial Public Offering (IPO). The company is known for its Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology, used to manufacture Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs) across six therapeutic segments.
Apart from sterile liquids, the company also manufactures medical devices with closure systems like nipple head, twist-off, lever-lock, and screw types, and packaging ranging from 2ml to 1000ml.
invest Now
Angle One : Click here
Grow : Click here to invest
Objects of the Issue
The IPO proceeds will be used for:
Setting up a new manufacturing line of SteriPort at Hariyala, District Kheda, Gujarat.
Setting up a new SVP manufacturing line at Hariyala, District Kheda, Gujarat.
Meeting General Corporate Purposes.
💹 Amanta Healthcare IPO GMP Today
👉 (GMP will be updated here once available in the grey market.)
Amanta Healthcare Business & Financials
Amanta Healthcare Financials
| Particulars (₹ in Cr.) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Borrowings | 215 | 205 | 195 |
| Net Worth | 62 | 66 | 96 |
| Revenue from Operations | 259 | 280 | 274 |
Amanta Healthcare IPO Dates
| Event | Date |
|---|---|
| IPO Open Date | 01 September 2025 |
| IPO Close Date | 03 September 2025 |
| Basis of Allotment | 04 September 2025 |
| Listing Date | 09 September 2025 |
| Listing On | BSE, NSE |
Amanta Healthcare IPO Details
| Particulars | Details |
|---|---|
| Issue Size | ₹126.00 Cr |
| Price Band | ₹120 – ₹126 per share |
| Face Value | ₹10 |
| Total Shares Offered | 1,00,00,000 |
| Shares Offered to Public | 35,00,000 |
| Lot Size | 119 shares |
| Minimum Investment | ₹14,994 |
Retail Max Investment |
1,547 shares / ₹1,94,922 |
Category-Wise Share Allocation
| Category | Shares Allocated | Percentage |
|---|---|---|
| Anchor Investors | 30,00,000 | 30% |
| Qualified Institutional Buyers (QIB) | 20,00,000 | 20% |
| Non-Institutional Investors (NII) | 15,00,000 | 15% |
| Retail Individual Investors (RII) | 35,00,000 | 35% |
| Total | 1,00,00,000 | 100% |
Borrowings (₹ in Cr.)
FY23: 215
FY24: 205
FY25: 195
Net Worth (₹ in Cr.)
FY23: 62
FY24: 66
FY25: 96
Revenue from Operations (₹ in Cr.)
FY23: 259
FY24: 280
FY25: 274
💡 The company has reduced borrowings and improved net worth year-on-year, although FY25 revenue showed a slight dip compared to FY24.
📅 Amanta Healthcare IPO Dates
IPO Open Date: 01 September 2025
IPO Close Date: 03 September 2025
Basis of Allotment: 04 September 2025
Listing Date: 09 September 2025
Listing On: BSE, NSE
💰 Amanta Healthcare IPO Details
Issue Size: ₹126.00 Cr
Price Band: ₹120 – ₹126 per share
Face Value: ₹10
Total Shares Offered: 1,00,00,000
Shares Offered to Public: 35,00,000
Lot Size: 119 shares
Minimum Investment: ₹14,994
Retail Max Investment: 1,547 shares / ₹1,94,922
📌 Category-Wise Share Allocation
Anchor Investors: 30,00,000 (30%)
Qualified Institutional Buyers (QIB): 20,00,000 (20%)
Non-Institutional Investors (NII): 15,00,000 (15%)
Retail Individual Investors (RII): 35,00,000 (35%)
Total Shares Offered: 1,00,00,000 (100%)
Positive Points (Strengths / Opportunities):
Strong Presence in Parenterals Market – The company operates in sterile liquid products (LVP & SVP), which have high demand in healthcare.
Diverse Product Portfolio – Presence in 6 therapeutic segments leads to risk diversification.
Revenue Stability—Revenue is stable between 259 and 280 Cr in FY23–FY25, meaning demand is consistent.
Reduced Borrowings – The Company has reduced its debt from 215 Cr (FY23) to 195 Cr (FY25).
Improving Net Worth – Net worth has increased from 62 Cr (FY23) to 96 Cr (FY25), which shows improvement in financial health.
Growth Potential in the Pharma Sector—The demand for healthcare and injectables is continuously increasing in India and globally.
✅ Key Highlights for Investors
Strong presence in sterile liquid & parenteral pharma segment.
Use of advanced ABFS & ISBM technology.
Wide range of medical devices and closure systems.
Net worth growing steadily, borrowings under control.
Expanding capacity with new manufacturing facilities in Gujarat.
⚠️ Risks to Consider
Revenue decline in FY25 vs FY24.
Highly regulated pharmaceutical sector with strict compliance needs.
Raw material dependency and global supply chain risks.
📌 Final Verdict
The Amanta Healthcare IPO offers investors a chance to participate in a pharmaceutical company with strong technology, diversified products, and expansion plans. While financials show stability, investors should also factor in the slight dip in FY25 revenues before making their decision.
🌐 Follow me on X: Click here.
📸 Instagram: Click here.
📹 whatsapp: Click here.
🔗 Facebook: Click here.